Frontlight ResearchEarly access
Active, not recruitingNo phase
An Adjunct Study to Assess Guided ADHD Therapy for Managing the Extent and Severity of Symptoms
Key facts
- Who runs it
- Lumos Labs, Inc.
- Where
- Berlin, Brentwood, Jacksonville, Lakeland, and Rochester Hills, United StatesSee the 5 sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 194 people enrolled
- Started
- 15 Apr 2023
- Ended
- Jun 2025
- Type of study
- Interventional
- Treatments tested
- ADHD Therapy
- Record updated
- 31 December 2024
Who can take part
- Age
- 18 years to 55 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 25 criteriaShow less
Who can take part
- 22-55 years of age (Cohort I) or 18-21 years of age (Cohort II)
- Confirmed ADHD diagnosis, combined or inattentive type, at Screening based on DSM-5 criteria and established via the MINI-Adult, administered by a trained clinician
- Baseline total score on the DSM 5 Inattentive Symptoms, DSM 5 Hyperactive - Impulsive Symptoms and ADHD Index subscales of the Conners' Adult ADHD Rating Scales-Investigator Rated: Long Version (CAARS-Inv:L) ≥24
- Current, stable use of an FDA approved pharmacological treatment for ADHD for at least 4 weeks prior to screening, but ADHD condition inadequately managed by that medication
- Ability to understand and speak English, follow written and verbal instructions (English), as assessed by the PI and/or Study Coordinator, and give informed consent (English)
- Have ability to connect wireless devices to a functional wireless network daily
- Have access to a computer or smart device (e.g., phone, tablet) with internet access and a Google Chrome web browser
- Ability to comply with all the testing and study requirements
Who cannot take part
- Inadequate IQ to participate in the study as estimated by Investigator (i.e., inability to read/understand the informed consent; inability to understand how the device and therapy (games) work)
- Have previously been assessed by TOVA for potential enrollment in a clinical trial
- Have previously used a videogame-like digital therapy (e.g., Akili EndeavorRxTM) OR within the last three years, have used a cognitive or brain training platform (e.g., Peak, Brain HQ, Lumosity, Atentiv) for more than two weeks duration
- Initiation within the last 4 weeks of behavioral therapy or neurofeedback, or planned initiation during the study. Patients who have been in behavior therapy or neurofeedback consistently for more than 4 weeks may participate provided their routine is unchanged during the course of the study. Patients planning on changing or initiating behavior therapy or neurofeedback during the course of the study will be excluded
- Positive urine drug screen
- Any use of psychoactive drugs (other than ADHD medication) that in the opinion of the Investigator may confound study data/assessments
- Has participated in a clinical trial within 90 days prior to screening
- Unstable/uncontrolled, comorbid psychiatric diagnosis, based on clinical interviewing, with significant current active symptoms including but not limited to posttraumatic stress disorder, schizophrenia spectrum and other psychotic disorders, bipolar disorder, autism spectrum disorder, severe obsessive-compulsive disorder, severe depressive or severe anxiety disorder, conduct disorder, or other symptomatic manifestations that in the opinion of the Investigator may confound study data/assessments
- Motor condition (e.g., physical deformity of the hands/arms; protheses) that prevents game playing as observed by the Investigator
- History of seizures (excluding febrile seizures), or significant motor or vocal tics, including but not limited to Tourette's Disorder and photo-sensitive epilepsy
- Any other condition that in the opinion of the Investigator may confound study data/assessments
- PHQ-9 scores ≥16
- Known sensitivity to playing video games, such as headaches, dizziness, nausea
- Patient is currently considered a suicide risk in the opinion of the Investigator, as measured by C-SSRS at screening (i.e., score of 4 or 5 on C-SSRS)
- Recent history (within the past 12 months) of suspected alcohol or substance abuse or dependence
- Visual acuity that cannot be corrected that prevents or negatively impacts game playing as observed by the Investigator
- Has a family member or close friend/associate also enrolled/currently participating in the same study
Where in United States
- Hassman Research InstituteBerlin, United States
- Midwest Research GroupBrentwood, United States
- CNS Healthcare of JacksonvilleJacksonville, United States
- Lakeland, FloridaHospital not named in the registry
- Rochester Center for Behavioral Medicine (RCBM)Rochester Hills, United States
About the trial
What the trial wants to find out
The objective of this study is to assess the safety and effectiveness of an at-home, game-based digital therapy for treating adult patients with Attention-Deficit/Hyperactivity Disorder (ADHD).
The group in the trial
- ADHD TherapyTreatment being tested
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- An Adjunct Study to Assess Guided ADHD Therapy for Managing the Extent and Severity of Symptoms - A Prospective, Multicenter, Open Label, Single Arm, Intervention Study to Assess Efficacy and Safety of an At-home, Game-based Digital Therapy for Treating Clinical Symptoms of Adult Patients With Attention-Deficit/Hyperactivity Disorder (ADHD)
- Record updated
- 31 December 2024